A Study of Oral TP-3654 in Patients With Myelofibrosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- High-Risk Primary Myelofibrosis
- High-Risk Secondary Myelofibrosis
- Intermediate-2 Myelofibrosis
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive ruxolitinib or fedratinib.
This study will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive ruxolitinib or fedratinib.
Tracking Information
- NCT #
- NCT04176198
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon